The primary objective of this research is to study the efficacy and safety of daily, home-based hyperthermic baths for reducing epileptic seizures in CDKL5 Deficiency Disorder.
This is a prospective, randomized, open-label, blinded-endpoint study designed to evaluate the efficacy and safety of daily home-based hyperthermic bathing in participants with CDKL5 deficiency disorder. Eligible participants will be randomized in a 1:1 ratio to receive either hyperthermic baths in addition to usual antiseizure care or usual antiseizure care alone without hyperthermic baths. Efficacy will be assessed primarily by changes in epileptic seizure burden, and safety will be evaluated throughout the study period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
34
A 12-week daily home-based hyperthermic bathing intervention consisting of immersion in a 40-42°C water bath for 20 minutes per session under continuous parental supervision. The intervention will be administered according to the study protocol.
Seizure Responder Rate
The proportion of participants achieving at least a 50% reduction in seizure frequency from baseline during the 12-week home-based hyperthermic baths period.
Time frame: Baseline to week 12 at home-based hyperthermic baths phase
Change in Seizure Frequency
Change in the frequency of epileptic seizures from baseline to the 12-week home-based hyperthermic baths period.
Time frame: Baseline to week 12 at home-based hyperthermic baths phase
Seizure-free Days
Number of days without epileptic seizures during the 12-week treatment period.
Time frame: Baseline to week 12 at home-based hyperthermic baths phase
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.